Pfizer's Lorbrena, or lorlatinib, has received expanded FDA approval as treatment for metastatic non-small cell lung cancer in patients with anaplastic lymphoma kinase-positive tumors. The FDA also granted approval to Ventana Medical System's Ventana ALK (D5F3) CDx Assay for use as companion diagnostic test for Lorbrena.